Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey
- 7 August 2019
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 32 (5), e13060
- https://doi.org/10.1111/dth.13060
Abstract
Click on the article title to read more.Keywords
This publication has 6 references indexed in Scilit:
- Systemic therapies of pityriasis rubra pilaris: a systematic reviewJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2018
- Biologics for pityriasis rubra pilaris treatment: A review of the literatureJournal of the American Academy of Dermatology, 2018
- Ustekinumab treatment of pityriasis rubra pilaris: A report of five casesThe Journal of Dermatology, 2018
- Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor ApremilastJAMA Dermatology, 2016
- Treatment Options for Pityriasis Rubra Pilaris Including Biologic AgentsJAMA Dermatology, 2014
- Pityriasis Rubra PilarisAmerican Journal of Clinical Dermatology, 2010